BamSEC and AlphaSense Join Forces
Learn More

ANI Pharmaceuticals Inc.

NASDAQ: ANIP    
Share price (11/4/24): $56.01    
Market cap (11/4/24): $1.178 billion
Search in Documents
Key Exhibits
External Links

Indentures Filter

EX-4.1
from 8-K 104 pages ══════════════════════════════════════════════════════ ═══════════════════════════════════════════════════════ ANI Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association as Trustee ───────────────────── Indenture Dated as of August 13, 2024 ───────────────────── 2.25% Convertible Senior Notes Due 2029 ═══════════════════════════════════════════════════════ ═══════════════════════════════════════════════════════
12/34/56
EX-4.1
from 8-K 9 pages Schedule to Merger Agreement Registration Rights
12/34/56
EX-4.1
from 10-K 4 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.8
from S-3 42 pages ANI Pharmaceuticals, Inc. and , as Trustee, Indenture Dated as of Debt Securities Reconciliation and Tie Between Trust Indenture Act of 1939, as Amended, and the Indenture
12/34/56
EX-4.6
from S-3 59 pages ANI Pharmaceuticals, Inc. Issuer and as Trustee Indenture Dated as of , 20 Debt Securities
12/34/56
EX-4.2
from 8-K 80 pages Article 1 Scope of First Supplemental Indenture
12/34/56
EX-4.1
from 8-K 42 pages Indenture ANI Pharmaceuticals, Inc. and the Bank of New York Mellon as Trustee Indenture Dated as of December 10, 2014 Senior Debt Securities
12/34/56
EX-4.8
from S-3 48 pages Form of Indenture to Be Entered Into ANI Pharmaceuticals, Inc. and the Bank of New York Mellon as Trustee Indenture Dated as of , 2014 Subordinated Debt Securities
12/34/56
EX-4.7
from S-3 42 pages Form of Indenture to Be Entered Into ANI Pharmaceuticals, Inc. and the Bank of New York Mellon as Trustee Indenture Dated as of , 2014 Senior Debt Securities
12/34/56
EX-4.1
from 8-K 16 pages Common Stock Purchase Warrant Biosante Pharmaceuticals, Inc
12/34/56
EX-4.4
from S-8 2 pages Indenture or similar
12/34/56
EX-4.1
from 8-K 16 pages Common Stock Purchase Warrant Biosante Pharmaceuticals, Inc
12/34/56
EX-4.1
from 8-K 16 pages Common Stock Purchase Warrant Biosante Pharmaceuticals, Inc
12/34/56
EX-4.1
from 8-K 16 pages Common Stock Purchase Warrant Biosante Pharmaceuticals, Inc
12/34/56
EX-4.9
from 10-K 13 pages Biosante Pharmaceuticals, Inc. Replacement Warrant to Purchase Common Stock to Purchase [___] Shares of Common Stock
12/34/56
EX-4.1
from 8-K 16 pages Common Stock Purchase Warrant Biosante Pharmaceuticals, Inc
12/34/56
EX-4.1
from 10-Q 8 pages Biosante Pharmaceuticals, Inc. Warrant
12/34/56
EX-4.2
from 8-K 7 pages Biosante Pharmaceuticals, Inc., and U.S. Bank National Association, Trustee Supplemental Indenture Dated as of October 14, 2009 to Indenture Dated as of June 24, 2009 Relating to Cell Genesys, Inc. 3.125% Convertible Senior Subordinated Notes Due 2013 Supplemental Indenture
12/34/56
EX-4.1
from 8-K 7 pages Biosante Pharmaceuticals, Inc., and U.S. Bank National Association, Trustee Supplemental Indenture Dated as of October 14, 2009 to Indenture Dated as of October 20, 2004 Relating to Cell Genesys, Inc. 3.125% Convertible Senior Subordinated Notes Due 2011 Supplemental Indenture
12/34/56
EX-4.1
from 8-K 16 pages Common Stock Purchase Warrant Biosante Pharmaceuticals, Inc
12/34/56